U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21NO4.H3O4P
Molecular Weight 413.3588
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYCODONE PHOSPHATE

SMILES

OP(O)(O)=O.[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3OC

InChI

InChIKey=TZKVACZYAHJHRA-RKXJKUSZSA-N
InChI=1S/C18H21NO4.H3O4P/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;1-5(2,3)4/h3-4,13,16,21H,5-9H2,1-2H3;(H3,1,2,3,4)/t13-,16+,17+,18-;/m1./s1

HIDE SMILES / InChI

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H21NO4
Molecular Weight 315.3636
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html

Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
500.0 nM [EC50]
16000.0 nM [EC50]
4000.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PERCODAN-DEMI

Approved Use

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)

Launch Date

-6.224256E11
Primary
PERCODAN-DEMI

Approved Use

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)

Launch Date

-6.224256E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
19 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
22.2 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17.7 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
39.3 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15.7 ng/mL
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.9 ng/mL
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
128.2 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
133 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
268.2 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
113.3 ng × h/mL
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
99 ng × h/mL
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.9 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
3.55 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
3.85 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
55%
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
55%
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day single, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Co-administed with::
acetaminophen(1950 mg; single)
cocaine(1/4 g; single)
Sources:
healthy, 30 years
n = 1
Health Status: healthy
Age Group: 30 years
Sex: M
Population Size: 1
Sources:
Other AEs: Pulmonary edema...
Other AEs:
Pulmonary edema
Sources:
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 1.7%)
Dizziness (grade 1-2, 1.7%)
Abdominal pain (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Headache, Vomiting...
AEs leading to
discontinuation/dose reduction:
Headache (grade 1-2, 0.8%)
Vomiting (grade 1-2, 0.8%)
Nausea (grade 1-2, 0.8%)
Somnolence (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 6.3%)
Dizziness (grade 1-2, 4.8%)
Confusion (grade 1-2, 3.2%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Vomiting, Flu syndrome...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 1-2, 0.8%)
Flu syndrome (grade 1-2, 0.8%)
Confusion (grade 1-2, 0.8%)
Fatigue (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
6 mg 2 times / day single, oral (mean)
Studied dose
Dose: 6 mg, 2 times / day
Route: oral
Route: single
Dose: 6 mg, 2 times / day
Sources:
healthy, mean age 33 years
n = 35
Health Status: healthy
Age Group: mean age 33 years
Sex: M+F
Population Size: 35
Sources:
Disc. AE: Vomiting...
15 mg 1 times / day single, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: single
Dose: 15 mg, 1 times / day
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
healthy, mean age 36 years
n = 40
Health Status: healthy
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (2.5%)
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
AEs

AEs

AESignificanceDosePopulation
Pulmonary edema
30 mg 1 times / day single, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Co-administed with::
acetaminophen(1950 mg; single)
cocaine(1/4 g; single)
Sources:
healthy, 30 years
n = 1
Health Status: healthy
Age Group: 30 years
Sex: M
Population Size: 1
Sources:
Abdominal pain grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Dizziness grade 1-2, 1.7%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 1.7%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Headache grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Somnolence grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Confusion grade 1-2, 3.2%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Dizziness grade 1-2, 4.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 6.3%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Confusion grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Fatigue grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Flu syndrome grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting 11.4%
Disc. AE
6 mg 2 times / day single, oral (mean)
Studied dose
Dose: 6 mg, 2 times / day
Route: oral
Route: single
Dose: 6 mg, 2 times / day
Sources:
healthy, mean age 33 years
n = 35
Health Status: healthy
Age Group: mean age 33 years
Sex: M+F
Population Size: 35
Sources:
Vomiting 2.5%
Disc. AE
15 mg 1 times / day single, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: single
Dose: 15 mg, 1 times / day
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
healthy, mean age 36 years
n = 40
Health Status: healthy
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
yes
yes
yes
yes (co-administration study)
Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001).
Page: 7.0
yes
yes (co-administration study)
Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001).
Tox targets
PubMed

PubMed

TitleDatePubMed
Advancement of opioid analgesia with controlled-release oxycodone.
2001
Strategies for the treatment of cancer pain in the new millennium.
2001
The preemptive analgesic effect of intraarticular bupivacaine and morphine after ambulatory arthroscopic knee surgery.
2001 Apr
A curse and a cure. Is the crackdown on an abused drug causing needless suffering?
2001 Aug 6
OxyContin abuse.
2001 Feb
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
2001 Feb
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
2001 Feb
The potent perils of a miracle drug.
2001 Jan 8
Federal reports say oxycodone abuse is on the rise.
2001 Jul 1
Profits vs. pain relief.
2001 Jul 2
Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel.
2001 Jul 31
Preoperative diclofenac is a useful adjunct to spinal anesthesia for day-case varicose vein repair.
2001 Jul-Aug
A retrospective study of the effect of postoperative indomethacin rectal suppositories on the need for narcotic analgesia in patients who had a cesarean delivery while they were under regional anesthesia.
2001 Jun
Prescription for addiction?
2001 Mar
Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients.
2001 May
[Treatment of pain in cancer with systemically administered opioids].
2001 May 19
Conversion ratio and cost of oxycodone.
2001 May-Jun
OxyContin, the media, and law enforcement.
2001 May-Jun
Drug dependence studies and regulations: an overview of the past and present.
2001 Nov
Opioid therapy for chronic painful conditions.
2001 Oct
States respond to growing abuse of painkiller.
2001 Oct-Nov
Managing postoperative pain.
2001 Sep
Interscalene brachial plexus block with continuous intraarticular infusion of ropivacaine.
2001 Sep
The influence of anaesthesia and surgery on the circadian rhythm of melatonin.
2002 Jan
Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain.
2002 Jan
OxyContin Use and Abuse.
2002 Mar-Apr
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery.
2002 May
Sevoflurane versus halothane: effect of oxycodone premedication on emergence behaviour in children.
2002 May
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.
2002 Oct
Detection of cocaine analytes and opiates in nails from postmortem cases.
2002 Oct
Determination of 6-oxo-morphinans, as the oximes, by difference circular dichroism spectroscopy.
2002 Oct
[Pain therapy in rheumatic diseases. Oxycodon is not a weak opioid].
2002 Sep 12
Patents

Sample Use Guides

For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.
Route of Administration: Oral
Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:21:16 UTC 2023
Edited
by admin
on Sat Dec 16 18:21:16 UTC 2023
Record UNII
GRM3MU4DWP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYCODONE PHOSPHATE
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYL-, (5.ALPHA.)-, PHOSPHATE (1:1)
Systematic Name English
(4R,4AS,7AR,12BS)-4A-HYDROXY-9-METHOXY-3-METHYL-2,4,5,6,7A,13-HEXAHYDRO-1H-4,12-METHANOBENZOFURO(3,2-E)ISOQUINOLIN-7-ONE;PHOSPHORIC ACID
Systematic Name English
OXYCODONE PHOSPHATE SALT
Common Name English
Code System Code Type Description
CAS
1211844-14-2
Created by admin on Sat Dec 16 18:21:16 UTC 2023 , Edited by admin on Sat Dec 16 18:21:16 UTC 2023
PRIMARY
SMS_ID
300000041678
Created by admin on Sat Dec 16 18:21:16 UTC 2023 , Edited by admin on Sat Dec 16 18:21:16 UTC 2023
PRIMARY
PUBCHEM
68824785
Created by admin on Sat Dec 16 18:21:16 UTC 2023 , Edited by admin on Sat Dec 16 18:21:16 UTC 2023
PRIMARY
FDA UNII
GRM3MU4DWP
Created by admin on Sat Dec 16 18:21:16 UTC 2023 , Edited by admin on Sat Dec 16 18:21:16 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)